Skip to Content
Upcoming Webinar

February 2026 International Monthly Webinar

Date: February 19, 2026 | 2:00 PM
Date: Thursday, February 19
Time: 2 p.m. EST

Each month, we bring together voices from across the oncology care spectrum to share what’s new, what’s working, and what’s next. This month, we’re focusing on supportive care that strengthens the patient (and caregiver) experience, plus practical, safety-forward guidance on integrating emerging therapies in medically integrated oncology care.

This Month’s Lineup:

Opening remarks from Brandy Persson, PharmD, BCOP (Cone Health Cancer Care)

Evidence-Based Programming to Strengthen Couple Communication and Emotional Support During Cancer Treatment – Jennifer Hoang, PharmD (Texas Oncology), explores how emotional support and healthy communication impact psychosocial well-being during cancer treatment, reviews evidence-based relationship frameworks, and discusses how couples-focused interventions can be implemented in clinical support settings.

PQI in Action: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma – Emilie Aschenbrenner, PharmD, BCOP (Froedtert Health), reviews the clinical role and outpatient integration of epcoritamab, with practical guidance on prophylaxis, step-up dosing, supportive care workflows, and monitoring for CRS and ICANS to support safe initiation in medically integrated oncology practice.

EV-303 Update: Integrating Enfortumab Vedotin + Pembrolizumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer – Andrew Ruplin, PharmD (Fred Hutchinson Cancer Center & UW Medicine), breaks down the EV-303 phase 3 trial design and key efficacy outcomes and shares evidence-based strategies to monitor and manage enfortumab vedotin–associated adverse events, including dermatologic toxicity, peripheral neuropathy, hyperglycemia, and ocular reactions.

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.